



QR code for mobile view

Indications for HIV PrEP:

- History of unprotected sexual activity
- Other concurrent sexually transmitted infection (*Refer to STI CPG*)
- IV drug use
- High risk behavior
 - Drug and alcohol use
 - Multiple partners
 - Males who have sex with males
- Patient request
- Patients with history of more than one nPEP course

Exclusion Criteria:


- Positive HIV
- Pending or no HIV testing results within the past 7 days
- < 12 years of age
- < 35 kg
- Eligible for nPEP based on recent or new exposure to HIV infected body fluids (≤ 72 hours)
- History sexual activity with current illness:
 - Malaise
 - Fever
 - Sore Throat
 - Lymphadenopathy

Additional Provider Resources:

- [CDC CPG, 2021](#)
- [CDC's Clinical Provider's Supplement for PrEP](#)

Abbreviations:

ED = Emergency Department
 HCP = Health Care Provider
 HIV = Human Immunodeficiency Virus
 ID = Infectious Disease
 IM = Intramuscular
 nPEP = Non-occupational post-exposure prophylaxis
 PCC= Primary Care Clinic
 PrEP = Pre-exposure prophylaxis
 STI = Sexually Transmitted Infection



Special Considerations:
(consult Social Work for the following scenarios)

- Concern for abuse/assault
- Concern for human trafficking
- If pt age is < 17 years, consider age of partner
- Patient has developmental delay
- Patient with known pregnancy

Labs

- HIV Ag/Ab
- Hep C ab
- BMP
- Hep B Panel (sAg, sAb, cAb)

PrEP Discharge Education:

- [PrEP](#) does not protect against other STIs
- Take PrEP every day or as prescribed by HCP
- PrEP does not:
 - Impact birth control medications
 - Impact hormone therapy drugs

Additional Education Resources:

- [Healthy Sexual Behaviors Handout](#)
- [Your Test for HIV](#)

Medication Options for HIV Pre-Exposure Prophylaxis (PrEP)			
Medication	Dosage/Formulation/Sig	Indication	Contraindications
Truvada® (emtricitabine/tenofovir disoproxil fumarate)	1 tablet (200/300mg)* by mouth once daily while at risk for HIV exposure	<ul style="list-style-type: none"> • For people at risk of HIV exposure from sex or injection drug use • Primary choice for accessibility 	<ul style="list-style-type: none"> • Existing Renal Disease • CrCl < 60 mL/m2/min • Significant risk of bone
Descovy® (emtricitabine/tenofovir alafenamide)	1 tablet (200/25mg)* by mouth once daily while at risk for HIV exposure	<ul style="list-style-type: none"> • For assigned male at birth at risk of HIV exposure from sex • Patient has contraindication to Truvada 	<ul style="list-style-type: none"> • Indicated for patients with pre-existing renal disease or specific medical contraindication
Apretude (cabotegravir) *Not currently provided at CMKC - refer to provider locator link	Injectable cabotegravir (600mg/3mL)* IM given once every other month	<ul style="list-style-type: none"> • For people at risk of HIV exposure from sex • Patient unable to comply or tolerate oral meds • Some insurance providers require reason why patient failed oral treatment 	<ul style="list-style-type: none"> • Patients who are not able to comply with more frequent clinic visits and blood draws

*All medications are indicated for patients >12 years of age and weighing at least 35kg.